Drugdiscovery >> Drugs >> News
6170
Views
Eisai’s breast cancer drug launched in Russia - drugdiscovery.com
Eisai’s breast cancer drug launched in Russia - drugdiscovery.com


Halaven (eribulin mesylate), a novel anticancer agent developed by Eisai, has now been launched in Russia, where it is approved for the treatment of locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens including an anthracycline and a taxane.
Read More >>


Tags: Eisai, halaven, eribulin mesylate, breast cancer, Russia - September 14, 2013
Related Articles
5527
Views
Perjeta approved for early breast cancer Perjeta approved for early breast cancer
The FDA has granted accelerated approval to Roche's Perjeta (pertuzumab) as part of a complete treatment regimen for patients with HER2-positive, locally advanced, inflammatory or early stage breast c Read More >>

Tags: Perjeta, pertuzumab, Roche, FDA, approval, early breast cancer, inflammatory breast cancer, neoadjuvant, treatment

5398
Views
The growth of breast cancer market in the future The growth of breast cancer market in the future
According to findings from Decision resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, the breast cancer market will grow to more than $15 bil Read More >>

Tags: breast cancer, drugs, market, perjeta, afinitor, herceptin, palbociclib

4487
Views
Decitabine could help treat breast cancer Decitabine could help treat breast cancer
Decitabine is currently licensed for the treatment of acute myeloid leukaemia. It is one of the rare, FDA approved cancer drugs, that work as DNA methylation modifiers. The results of an animal study Read More >>

Tags: decitabine, breast cancer, study, leukaemia, acute myeloid leukaemia, epigenetics, methylation, PRKD1

2548
Views
Tamoxifen may prevent breast cancer Tamoxifen may prevent breast cancer
The results of the largest to date global study suggest that women who carry the BRCA1 or BRCA2 mutation which put them at high risk of developing breast cancer could benefit from taking tamoxifen fo Read More >>

Tags: Tamoxifen, breast cancer, prevention, BRCA 1, BRCA 2, mutation, high risk

5725
Views
Femara beneficial for breast cancer patients treated with tamoxifen Femara beneficial for breast cancer patients treated with tamoxifen
The results of a large study show that femara significantly reduces the risk of breast cancer reccurence in patients who were treated both drugs. Read More >>

Tags: breast cancer, femara, tamoxifen, risk, recurrence

2513
Views
FDA panel recommends Perjeta for neoadjuvant use in early breast cancer FDA panel recommends Perjeta for neoadjuvant use in early breast cancer
With FDA’s aim to get cutting-edge treatments to early-stage patients in hopes of stopping the disease in its tracks, Roche’s Perjeta is on its way to get a new indication for the treatment of pat Read More >>

Tags: Perjeta, early breast cancer, HER2-positive, neoadjuvant, before surgery

6006
Views
A positive review of  Roche’s  Perjeta in early stage breast cancer A positive review of Roche’s Perjeta in early stage breast cancer
The FDA has issued a positive review of Perjeta and recommended accelerating approval. In mid-stage trials, women with early-stage breast cancer who received the drug had significantly fewer tumor Read More >>

Tags: Perjeta, Roche, breast cancer, early stage, FDA, review

5162
Views
Long-term calcium-channel blocker therapy linked to increased breast cancer risk Long-term calcium-channel blocker therapy linked to increased breast cancer risk
A case-control study showed that the risk of breast cancer more than doubled in postmenopausal women who were on a long-term calcium- channel blocker therapy. Women who were on other types of heart dr Read More >>

Tags: calcium-channel blocker,long-term therapy, breast cancer, diuretics, beta-blockers, ACE inhibitors, or angiotensin receptor blockers

6240
Views
The first approved treatment for negative symptoms in schizophrenia to be launched in 2016 The first approved treatment for negative symptoms in schizophrenia to be launched in 2016
Roche/Chugai's glycine transporter-1 inhibitor bitopertin is poised to be the first-in-class agent for the treatment of negative symptoms in schizophrenia. The launch in the United States and Europe ( Read More >>

Tags: bitopertin, Roche, negative symptoms in schizophrenia, schizophrenia, symptoms, negative, new drug, new therapy

5392
Views
Chemotherapy Drugs for Breast Cancer Chemotherapy Drugs for Breast Cancer
Cancer is the second leading cause of death and cancer of the breast is the most common form. The overall rate of this cancer is 1 in every 8 women. That statistic will change according Read More >>

Tags: Chemotherapy drugs, breast cancer

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013